Bellwether Advisors LLC Acquires New Holdings in Bristol Myers Squibb Company $BMY

Bellwether Advisors LLC bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the first quarter, HoldingsChannel reports. The firm bought 31,105 shares of the biopharmaceutical company’s stock, valued at approximately $1,887,000.

Several other institutional investors and hedge funds also recently modified their holdings of BMY. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the 4th quarter worth approximately $1,947,272,000. AQR Capital Management LLC lifted its stake in Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after buying an additional 16,332,924 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Bristol Myers Squibb by 47.0% during the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock valued at $1,321,308,000 after buying an additional 7,837,485 shares during the last quarter. Geode Capital Management LLC grew its holdings in Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after buying an additional 6,084,046 shares during the last quarter. Finally, Man Group plc increased its position in Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after buying an additional 5,503,391 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA collaboration and plans to deploy a next-generation DGX SuperPOD AI system to speed drug discovery, a potentially positive long-term productivity and innovation catalyst. Article Title
• Positive Sentiment: The company said it will be the first life sciences firm to buy NVIDIA’s DGX SuperPOD based on Vera Rubin systems, highlighting an aggressive push into advanced AI infrastructure for drug development. Article Title
• Positive Sentiment: Bristol Myers is also being viewed as a peer in next-generation cancer treatment innovation, with its bispecific antibody work alongside BioNTech mentioned in coverage of therapies that could help replace older blockbuster drugs over time. Article Title
• Neutral Sentiment: Healthcare stocks traded lower late Monday afternoon, which could have offset some of the positive company-specific momentum in BMY. Article Title

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Guggenheim reiterated a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Cantor Fitzgerald restated a “neutral” rating and issued a $54.00 target price on shares of Bristol Myers Squibb in a report on Monday, July 6th. Finally, Bank of America decreased their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $61.25.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $60.89 on Wednesday. The company has a market cap of $124.34 billion, a P/E ratio of 17.10, a P/E/G ratio of 0.17 and a beta of 0.23. The business has a fifty day simple moving average of $57.20 and a 200-day simple moving average of $57.90. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same period in the prior year, the business posted $1.80 earnings per share. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.34 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.